Intensive Adjuvant Therapy for TNBC with BRCA Gene Mutation

Launched by CANCER INSTITUTE AND HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES · May 4, 2024

Keywords

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • ECOG score 0-1
• • TNBC
• • BRCA1/2 mutation
• • No distant metastases assessed by imaging after surgical treatment
• • Breast cancer that is non-pCR after neoadjuvant therapy, or postoperative pathology suggestive of ≥pT2, or ≥pN1
• • Have completed postoperative adjuvant chemotherapy and/or radiotherapy
• • No major organ dysfunction
• Exclusion Criteria:
• • Patients who are unable to take oral medication, or who refuse this medication regimen
• • Already enrolled in another study, or less than or equal to 4 weeks from discontinuation of another medication
• • Presence of severe dysfunction of vital organs
• • Patients with other malignancies (with the exception of cured non-melanoma skin cancers, carcinoma in situ of the cervix and other tumours that have been cured for at least 5 years)
• • Acute infectious disease or active chronic infectious disease
• • History of uncontrolled epilepsy, central nervous system disease or mental disorder